Thermo Fisher Scientific SG&A remained flat by 0.0% to $2.18B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 0.9%, from $2.20B to $2.18B. Over 4 years (FY 2021 to FY 2025), SG&A shows relatively stable performance with a 2.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
is_selling_general_and_administrative| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$42.00M | $59.00M | $7.97B | $2.28B | $2.21B | $2.21B | $2.30B | $2.12B | $2.15B | $2.05B | $2.13B | $2.18B | $2.11B | $2.10B | $2.20B | $2.18B | $2.18B | $2.18B | $2.18B |
| QoQ Change | — | +240.5% | >999% | -71.4% | -3.0% | -0.0% | +4.1% | -7.8% | +1.2% | -4.5% | +4.1% | +2.4% | -3.3% | -0.6% | +5.0% | -0.9% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | >999% | >999% | -71.2% | -6.9% | -2.9% | -7.2% | -7.3% | +3.0% | -1.6% | +2.4% | +3.3% | +0.0% | +3.4% | +4.1% | -0.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.